Santarus Completes Patient Enrollment in CONTRIBUTE Study with UCERIS
July 18, 2013 at 07:04 AM EDT
Santarus, Inc. (NASDAQ: SNTS ) today announced the completion of enrollment in the CONTRIBUTE clinical study designed to evaluate the incremental benefit of adding UCERIS (budesonide) extended release
